{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"174-310-422-492-548","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"174-310-422-492-548","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8878,"type":"PATENT","title":"Kyoto University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":10470,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8212,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately = \"Kyoto University\", \"Kyoto Univ\", \" Univ Kyoto\", \" University Kyoto\", \"Kyot* Univ*\", \"Univ* Kyot*\".
Select more for variants
Add to collection
Select the collection expanded by simple families
Add to collection
Search Applicants and Owners separately = \"Kyoto University\", \"Kyoto Univ\", \" Univ Kyoto\", \" University Kyoto\", \"Kyot* Univ*\", \"Univ* Kyot*\".
Select more for variants
Add to collection
Select the collection expanded by simple families
Add to collection
(i) culturing the human pluripotent stem cell in a medium containing Activin A and Wnt or a functional equivalent of Wnt, and then\n
(ii) culturing the cell obtained in the step (i) in a medium containing BMP and Wnt or a functional equivalent of Wnt."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the intermediate mesoderm cell is an OSR1-positive cell."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein in the culture of the step (i), the human pluripotent stem cell is cultured in suspension to form a cell population or cell mass of the human pluripotent stem cell, and in the culture of the step (ii), the cell population or the cell mass is subjected to adhesion culture, thereby forming the intermediate mesoderm cell."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising, in the culture of the step (i), substantially separating the cell population or cell mass of human pluripotent stem cell into respective cells."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 4, wherein step (i) further comprises adhering the separated cells to a Matrigel™-coated dish or a collagen-coated dish and then culturing the cells."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein in the step (i), the medium further contains fetal bovine serum (FBS)."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein in the step (ii), the medium further contains a knockout serum replacement (KSR)."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the Wnt is Wnt3 a."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the functional equivalent of Wnt is a GSK3β inhibitor."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein the GSK3β inhibitor is CHIR99021."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the BMP is BMP7."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 3, wherein the culture in the step (i) is performed for a culture period ranging from 2 to 5 days, preferably 2 days, and the culture in the step (ii) is performed for a culture period ranging from 14 to 18 days, preferably 16 days."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 4, wherein the culture in the step (i) is performed for a culture period ranging from 2 to 5 days, preferably 2 days, and the culture in the step (ii) is performed for a culture period ranging from 7 to 10 days, preferably 8 days."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the human pluripotent stem cell is a human iPS cell or a human ES cell."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the human pluripotent stem cell has a foreign reporter gene in the chromosome, wherein expression of the gene is interlocked with the expression of endogenous OSR1."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the reporter gene is a DNA encoding a fluorescent protein, a luminescent protein, GUS, or LacZ."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the pluripotent stem cell is a human iPS cell."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["A method for producing a metanephric cell, comprising inducing intermediate mesoderm from a human pluripotent stem cell by the method of claim 1 comprising the steps (i) and (ii) and further continuously performing the step (ii) to produce the metanephric cell."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["A human pluripotent stem cell having a foreign reporter gene in the chromosome, wherein the gene is expressed interlocked with the expression of endogenous OSR1."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The human pluripotent stem cell of claim 19, wherein the reporter gene is a DNA encoding a fluorescent protein, a luminescent protein, GUS, or LacZ."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The human pluripotent stem cell of claim 19, wherein the pluripotent stem cell is a human iPS cell."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["A method for screening for an inducer for differentiation into intermediate mesoderm, wherein the method comprises culturing the human pluripotent stem cell of claim 19 in the presence of a candidate substance and examining whether the candidate substance has an ability to induce the differentiation into intermediate mesoderm."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["A kit for inducing the differentiation into an intermediate mesoderm cell, comprising Activin A, Wnt or a functional equivalent thereof, and BMP, in different containers."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The kit of claim 23, wherein the Activin A and the Wnt or a functional equivalent thereof is contained in a culture medium."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The kit of claim 23, wherein the BMP and the Wnt or a functional equivalent thereof is contained in a culture medium."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The kit of claim 23, further comprising a human pluripotent stem cell."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The kit of claim 26, wherein the human pluripotent stem cell is a cell having a foreign reporter gene in the chromosome, wherein the gene is expressed interlocked with the expression of endogenous OSR1."],"number":27,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}